Keratin Tablets MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy FormulationBy End UseBy Dosage Form

Keratin tablets are oral dietary supplements formulated with hydrolyzed keratin protein, typically combined with biotin, collagen or other micronutrients, marketed for hair strength, skin elasticity and nail health. They are sold as standard, chewable or effervescent tablets through pharmacy, mass retail and online channels to adult consumers seeking a beauty-from-within routine, not a medical treatment for hair or skin conditions.

The global keratin tablets market is valued at USD 312.4 million in 2025 and is set to reach USD 576 million by 2034, a compound annual growth rate of 6.92% across the 2026-2034 forecast period. The study tracks the market across USD 208 million in 2020, USD 289 million in 2024, USD 337.5 million in 2026 and USD 448.3 million in 2030.

On the type axis, growth rates run from 5.82% for Alpha-keratin up to 8.94% for Beta-keratin. Alpha-keratin carries the volume: USD 212.43 million and 68% of revenue in 2025, USD 357.12 million and 62% in 2034. The lines gaining share are Beta-keratin. Alpha-keratin lose share without losing revenue.

The application split puts Pharmacy first, at USD 118.71 million and 38% of revenue in 2025, rising to USD 184.32 million and 32% in 2034. Online Store grows faster at 10.15% against 4.87%, moving from 35% of revenue to 46% by 2034. It cuts the same total as the type axis from a different commercial angle, so revenue does not add across the two.

Geographically, 42% of 2025 revenue sits in North America (USD 131.21 million rising to USD 218.88 million) ahead of Europe at 24% and USD 74.98 million. Middle East and Africa is smallest, at 5%. Share shifts toward Asia Pacific, Latin America and Middle East and Africa over the forecast period, so the regional split repays a close reading.

The 2025 total is triangulated from published sources and category proxies, with no independently sourced count behind it. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, two type lines and five segmentation axes across a fifteen-year window.

• Revenue grows from USD 312.4 million in 2025 to USD 576 million in 2034, a compound annual rate of 6.92%, having reached USD 289 million in 2024 from USD 208 million in 2020.
• The largest line by type is Alpha-keratin, worth USD 212.43 million and 68% of revenue in 2025, rising to USD 357.12 million and 62% by 2034.
• Fastest growth on the type axis belongs to Beta-keratin: 8.94% a year, USD 99.97 million to USD 218.88 million, and a share moving from 32% to 38%.
• Against a base case of USD 576 million in 2034, the study also reports a bear case at USD 497.5 million and a bull case at USD 657 million, with the assumptions behind each set out separately.
• North America holds 42% of global revenue in 2025 at USD 131.21 million, the largest of the five regions tracked, and reaches USD 218.88 million by 2034.
• 78% of North America's base-year revenue comes from the United States alone: USD 102.34 million in 2025, rising to USD 168.54 million by 2034, which is why it is that region's worked example.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

Three things move over 2026-2034, and they are worth separating: the type mix, the regional balance, and the 6.92% compounding underneath both.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Composition shifts on the type axis. Between 2026 and 2034, 8.94% growth in Beta-keratin against 5.82% in Alpha-keratin pulls the type mix apart. Over the forecast period that moves Beta-keratin from 32% of revenue to 38%, and Alpha-keratin from 68% to 62%. The revenue figures behind that are USD 99.97 million to USD 218.88 million and USD 212.43 million to USD 357.12 million. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 22% of revenue in 2025 to 27% in 2034, worth USD 68.73 million rising to USD 155.52 million; Latin America moves from 7% of revenue in 2025 to 7.5% in 2034, worth USD 21.87 million rising to USD 43.2 million; Middle East and Africa moves from 5% of revenue in 2025 to 5.5% in 2034, worth USD 15.62 million rising to USD 31.68 million. The offsetting side is North America at 42% moving to 38%, Europe at 24% moving to 22%, none of which contracts. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

The series never breaks trajectory. Reading the series: USD 208 million in 2020, USD 289 million in 2024, USD 312.4 million in 2025, USD 337.5 million in 2026, USD 448.3 million in 2030 and USD 576 million in 2034. The forecast rate of 6.92% sits against 8.47% over the historical period, so the projection extends an observed trend instead of proposing a new one. The risk in the number sits in the mix assumptions, not in whether the market grows at all, which is where the type and regional sections come in.

Growth is concentrated in Beta-keratin

Three sources account for the growth to 2034: 6.92% compounding across the base, share moving toward the faster type lines, and above-market expansion in the leading regions.

Downside case: USD 497.5 million by 2034, against USD 576 million in the base case

Upside case: USD 657 million by 2034

The total depends on a single line

42% of the global keratin tablets market sits in North America in 2025, worth USD 131.21 million and reaches USD 218.88 million by 2034. Among the five regions it ranks first by revenue in both years.

Share settles at 38% in 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

Segment composition follows the global pattern: Alpha-keratin largest at 68% of 2025 revenue, Beta-keratin fastest at 8.94%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

The United States is the largest market within North America, generating USD 102.34 million in 2025 and projected to reach USD 168.54 million by 2034. At 78% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Set against USD 131.21 million and USD 218.88 million for the region, it is why this market, and not a smaller one, is the one reported in full.

The type pattern in the United States is the global one: 68% of 2025 revenue in Alpha-keratin, 62% by 2034, against 8.94% growth in Beta-keratin taking it from 32% to 38%. Its 78% weight in North America means those movements carry straight into the regional totals. Revenue by type for the United States is reported separately in the full report.

The Food and Drug Administration regulates keratin tablets as a dietary supplement under the Dietary Supplement Health and Education Act, which classifies the product as food, not a drug. Manufacturers must comply with dietary supplement current good manufacturing practice requirements covering identity, purity, and composition testing. Labeling must carry a Supplement Facts panel, correctly identify keratin as the ingredient and its source, and avoid disease claims; structure-function claims are permitted only with the standard disclaimer that the FDA has not evaluated the statement. No premarket approval is required unless the formulation introduces a new dietary ingredient, in which case a safety notification must be filed before marketing.

In the United States the field is Garden of Life, Kerotin, Nature's Truth, Nature's Bounty and Nature Made. Volume sits in Alpha-keratin at 68% of 2025 revenue; movement sits in Beta-keratin at 8.94% growth. The full report covers country-level positioning and shares company by company; this summary does not.

Canada is sized at USD 24.93 million in 2025, rising to USD 41.59 million by 2034; 7.98% of global revenue and 19% of North America. It is reported separately from the United States across every segmentation axis in the full report.

Europe holds 24% of the global keratin tablets market in 2025, worth USD 74.98 million and reaches USD 126.72 million by 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.

Share settles at 22% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

Within the region the type split tracks the global one; 68% of 2025 revenue in Alpha-keratin, fastest growth of 8.94% in Beta-keratin. Europe is reported axis by axis and country by country in the full study.

USD 20.24 million of Europe's 2025 revenue is generated in Germany, the region's largest market, reaching USD 32.95 million by 2034. It accounts for 27% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 74.98 million to USD 126.72 million over the same period, and this is the market carrying the country-level detail in the full report.

Germany buys along the same lines as the market globally; Alpha-keratin first at 68% of 2025 revenue and 62% in 2034, Beta-keratin fastest at 8.94% on a share moving from 32% to 38%. Its 27% weight in Europe means those movements carry straight into the regional totals. The full report reports Germany by type separately.

In Germany, keratin tablets fall under the European Union's food supplement regime, enforced domestically through the Bundesamt für Verbraucherschutz und Lebensmittelsicherheit and the food surveillance authorities of the individual federal states. The product must be notified to the competent authority before sale and must meet the compositional and labelling standards set out in the Food Supplements Directive as transposed into German law. Any statement made about keratin's effect on hair or nails must be an authorised health claim under the EU Health Claims Regulation; unauthorised or implied claims are not permitted. Packaging must display the supplement's ingredient composition, intended use, and a warning against exceeding the recommended intake, printed in German.

Garden of Life, Kerotin, Nature's Truth, Nature's Bounty and Nature Made are the suppliers covered in Germany. The commercially relevant division is 68% of 2025 revenue in Alpha-keratin, where the volume is, against 8.94% growth in Beta-keratin, where share moves. That makes Europe a 24% share of 2025 global revenue, USD 74.98 million rising to USD 126.72 million, for any supplier deciding where to concentrate.

The United Kingdom is sized at USD 16.5 million in 2025, rising to USD 26.61 million by 2034; 5.28% of global revenue and 22% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

3.84% of global revenue is generated in France; USD 12 million in 2025, reaching USD 20.28 million in 2034, and 16% of Europe.

USD 68.73 million of 2025 revenue is generated in Asia Pacific, 22% of the global keratin tablets market rising to USD 155.52 million in 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

By 2034 the share has moved up to 27%, at a pace above the 6.92% global rate, so this region warrants separate treatment and should not be scaled off the total.

Within the region the type split tracks the global one; 68% of 2025 revenue in Alpha-keratin, fastest growth of 8.94% in Beta-keratin. The full report breaks Asia Pacific out along every axis and by country.

USD 23.37 million of Asia Pacific's 2025 revenue is generated in China, the region's largest market, reaching USD 54.43 million by 2034. At 34% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Against regional totals of USD 68.73 million in 2025 and USD 155.52 million in 2034, it is the country the full report breaks out in detail.

China buys along the same lines as the market globally; Alpha-keratin first at 68% of 2025 revenue and 62% in 2034, Beta-keratin fastest at 8.94% on a share moving from 32% to 38%. Because the country carries 34% of Asia Pacific, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by type for China is reported separately in the full report.

In China, keratin tablets marketed with a stated functional benefit are treated as health food under the framework administered by the National Medical Products Administration, successor to the earlier health food approval system. Depending on the ingredient and the claim made, a supplier must either register the product and submit safety and efficacy evidence for review, or file a simplified notification for ingredients already recognised as permitted. Approved products carry the designated health food mark on their packaging alongside mandatory Chinese-language labelling stating composition, function claim, and consumption guidance. Products without an approved functional claim may instead be sold as an ordinary food, provided no health or therapeutic benefit is stated on the label or in marketing.

The suppliers tracked in this study (Garden of Life, Kerotin, Nature's Truth, Nature's Bounty and Nature Made) compete in China across the type lines above. Two different problems sit on the same axis: holding Alpha-keratin at 68% of 2025 revenue, and taking Beta-keratin while it grows at 8.94%. Weighting toward Asia Pacific means competing for 22% of 2025 global revenue, a base of USD 68.73 million moving to USD 155.52 million across the forecast period.

4.4% of global revenue is generated in Japan; USD 13.75 million in 2025, reaching USD 28 million in 2034, and 20% of Asia Pacific.

Within Asia Pacific, India accounts for 15% of regional revenue and 3.3% of the global total, worth USD 10.31 million in 2025 and USD 26.44 million by 2034.

USD 21.87 million of 2025 revenue is generated in Latin America, 7% of the global keratin tablets market with USD 43.2 million projected for 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share has moved up to 7.5%, so the region grows faster than the market's 6.92% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

The type mix reported at global level applies here, with Alpha-keratin the largest line at 68% of 2025 revenue and Beta-keratin the fastest-growing at 8.94%. Latin America is reported axis by axis and country by country in the full study.

The largest single market in Latin America is Brazil, at USD 11.37 million in 2025 and USD 22.46 million in 2034. At 52% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. The region itself runs USD 21.87 million to USD 43.2 million over the same period, and this is the market carrying the country-level detail in the full report.

Brazil buys along the same lines as the market globally; Alpha-keratin first at 68% of 2025 revenue and 62% in 2034, Beta-keratin fastest at 8.94% on a share moving from 32% to 38%. Its 52% weight in Latin America means those movements carry straight into the regional totals. Per-type revenue for Brazil appears on its own in the full report.

In Brazil, keratin tablets are regulated by the Agência Nacional de Vigilância Sanitária as a food supplement under its rules governing suplementos alimentares. Suppliers must notify the product to Anvisa before marketing, demonstrating that the formulation and any nutrient or ingredient levels conform to the agency's technical standards for the category. Labelling must be in Portuguese, identify keratin and its source, state the recommended daily intake, and avoid any claim that the product treats, cures, or prevents disease, since such claims fall outside the supplement regime and would require registration as a medicine. Health claims regarding hair or nail benefit must be consistent with those the agency recognises for the category.

In Brazil the field is Garden of Life, Kerotin, Nature's Truth, Nature's Bounty and Nature Made. Alpha-keratin, at 68% of 2025 revenue, is where the volume sits, and Beta-keratin, growing at 8.94%, is where position changes hands over the forecast period. That makes Latin America a 7% share of 2025 global revenue, USD 21.87 million rising to USD 43.2 million, for any supplier deciding where to concentrate.

1.96% of global revenue is generated in Mexico; USD 6.12 million in 2025, reaching USD 12.1 million in 2034, and 28% of Latin America.

5% of the global keratin tablets market sits in Middle East and Africa in 2025, worth USD 15.62 million with USD 31.68 million projected for 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

By 2034 the share has moved up to 5.5%, at a pace above the 6.92% global rate, so this region warrants separate treatment and should not be scaled off the total.

The type mix reported at global level applies here, with Alpha-keratin the largest line at 68% of 2025 revenue and Beta-keratin the fastest-growing at 8.94%. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

USD 4.69 million of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 9.5 million by 2034. Its 30% of base-year regional revenue leads the region, though enough sits elsewhere that Middle East and Africa is not a proxy for it. Set against USD 15.62 million and USD 31.68 million for the region, it is why this market, and not a smaller one, is the one reported in full.

Composition here matches the global split: the largest line is Alpha-keratin at 68% of 2025 revenue, easing to 62% by 2034, and the fastest is Beta-keratin at 8.94%, from 32% to 38%. With 30% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Saudi Arabia carries its own type breakdown in the full report.

In Saudi Arabia, the Saudi Food and Drug Authority regulates keratin tablets as a dietary or food supplement product, requiring the supplier to register the formulation in the authority's product registration system before it can be sold in the market. Registration requires evidence that the composition and any listed ingredient conform to the applicable Gulf standardisation body specifications for supplement products, alongside a Saudi-specific safety and labelling review. Labels must appear in Arabic and English, disclose the ingredient list and intended use, and carry no claim that the product treats or prevents disease, since such statements would place the product under pharmaceutical regulation instead. Imported batches are also subject to border inspection by the authority before distribution.

In Saudi Arabia the field is Garden of Life, Kerotin, Nature's Truth, Nature's Bounty and Nature Made. The commercially relevant division is 68% of 2025 revenue in Alpha-keratin, where the volume is, against 8.94% growth in Beta-keratin, where share moves. That makes Middle East and Africa a 5% share of 2025 global revenue, USD 15.62 million rising to USD 31.68 million, for any supplier deciding where to concentrate.

Within Middle East and Africa, South Africa accounts for 22% of regional revenue and 1.1% of the global total, worth USD 3.44 million in 2025 and USD 6.65 million by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Type, Application, Formulation, End Use, Dosage Form, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.